Brief: Himalaya Therapeutics Announces Interim Phase 2 Results For Mecbotamab Vedotin
12/09/2022 15:11
Bioatla Inc BCAB.O :
* HIMALAYA THERAPEUTICS ANNOUNCES INTERIM PHASE 2 RESULTS
FOR
MECBOTAMAB VEDOTIN
* HIMALAYA THERAPEUTICS - PRELIMINARY OBSERVATIONS IN NSCLC
SUPPORT ADVANCING TO REGISTRATIONAL STAGE OF TRIAL; ANTICIPATE
FULL INTERIM DATA SET IN 4Q22
Source text for Eikon: ID:nPn88RHcfa
Further company coverage: BCAB.O
Recent news on Bioatla
See all newsBrief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM